-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The net result for the period of deducting operating expenses from operating revenues.
-
Summary
-
Adaptimmune Therapeutics PLC quarterly/annual Operating Income (Loss) history and growth rate from 2013 to 2023.
- Adaptimmune Therapeutics PLC Operating Income (Loss) for the quarter ending June 30, 2024 was $68.7M.
- Adaptimmune Therapeutics PLC Operating Income (Loss) for the twelve months ending June 30, 2024 was -$77.1M, a 32.1% increase year-over-year.
- Adaptimmune Therapeutics PLC annual Operating Income (Loss) for 2023 was -$140M, a 14.8% increase from 2022.
- Adaptimmune Therapeutics PLC annual Operating Income (Loss) for 2022 was -$164M, a 1.06% decline from 2021.
- Adaptimmune Therapeutics PLC annual Operating Income (Loss) for 2021 was -$162M, a 21.6% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)